Use of immune diversity as a predictive marker for identifying B-cell-lymphomas-patients having an increased risk of febrile or infectious event

摘要

The present invention pertains to the field of cancer therapy and provides a predictive marker for determining if a patient suffering from a B-cell neoplasm can benefit from an anti-CD20-based chemotherapy.